A compromise is reached regarding a COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 do not need to seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.
A panel of external experts to the U.S. Food and Drug Administration unanimously vote that the benefits of the gene replacement treatment made by Spark Therapeutics of Philadelphia, Pennsylvania, called voretigene neparvovec (trade name, Luxturna), which treats Leber's congenital amaurosis (LCA), a form of hereditary blindness, outweigh its risks. The treatment, which targets a specific disease-causing mutation, is designed to treat individuals who have two mutated copies of a gene called "RPE65" and consists of a virus injected into the eye loaded with a normal copy of the "RPE65" gene. Further, this technique utilizing adeno-associated virus as a vector may, in the future, be used for the treatment of heart disease and also mutations other than LCA, including some cancers.